Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumors × zansecimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

Paclitaxel 11 atezolizumab 9 Gemcitabine 9 pembrolizumab 8 Carboplatin 6 Irinotecan 5 Injections 5 Docetaxel 5 Cetuximab 5 navitoclax 4 Leucovorin 4 Fluorouracil 4 olaparib 3 Oxaliplatin 3 Nivolumab 3 Bevacizumab 3 zolbetuximab 2 tocilizumab 2 tivozanib 2 tislelizumab 2 spartalizumab 2 ridaforolimus 2 plocabulin 2 liposomal doxorubicin 2 linifanib 2 lenvatinib 2 ipatasertib 2 envafolimab 2 cobimetinib 2 brigimadlin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡